BCLI Key Statistics, Chart & Performance
The current stock price of BCLI is 1.17 USD. In the past month the price decreased by -1.68%. In the past year, price decreased by -77.48%.
BCLI Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to BCLI. When comparing the yearly performance of all stocks, BCLI is a bad performer in the overall market: 91.02% of all stocks are doing better.
BCLI Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to BCLI. BCLI may be in some trouble as it scores bad on both profitability and health.
BCLI Financial Highlights
Over the last trailing twelve months BCLI reported a non-GAAP Earnings per Share(EPS) of -2.07. The EPS increased by 21.54% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -310.45% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
BCLI Forecast & Estimates
7 analysts have analysed BCLI and the average price target is 15.47 USD. This implies a price increase of 1222.51% is expected in the next year compared to the current price of 1.17.
BCLI Ownership
BCLI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.96 | 398.827B | ||
| AMGN | AMGEN INC | 16.25 | 182.324B | ||
| GILD | GILEAD SCIENCES INC | 16.37 | 177.765B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.11 | 118.135B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.68 | 79.79B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.14 | 46.476B | ||
| INSM | INSMED INC | N/A | 33.518B | ||
| NTRA | NATERA INC | N/A | 31.422B | ||
| BIIB | BIOGEN INC | 12.01 | 25.931B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.38 | 20.594B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About BCLI
Company Profile
Brainstorm Cell Therapeutics, Inc. is a biotechnology company, which develops and commercializes autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis, Progressive Multiple Sclerosis, Alzheimer's disease, and other neurodegenerative diseases. The company is headquartered in New York City, New York and currently employs 27 full-time employees. The company went IPO on 2003-05-28. The firm is in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease; progressive multiple sclerosis (PMS); Alzheimer’s disease (AD); and other neurodegenerative diseases. Its NurOwn, a cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived MSCs to secrete high levels of neurotrophic factors (NTFs), modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. The company has completed a Phase III pivotal trial in ALS (NCT03280056); this trial investigated the safety and efficacy of repeat-administration of autologous MSC-NTF cells. The firm's wholly owned subsidiary, Brainstorm Cell Therapeutics Ltd. holds exclusive rights to commercialize NurOwn technology.
Company Info
BRAINSTORM CELL THERAPEUTICS
1325 Avenue Of Americas, 28th Floor
New York City NEW YORK 10019 US
CEO: Chaim Lebovits
Employees: 27
Phone: 12014880460
BRAINSTORM CELL THERAPEUTICS / BCLI FAQ
What does BRAINSTORM CELL THERAPEUTICS do?
Brainstorm Cell Therapeutics, Inc. is a biotechnology company, which develops and commercializes autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis, Progressive Multiple Sclerosis, Alzheimer's disease, and other neurodegenerative diseases. The company is headquartered in New York City, New York and currently employs 27 full-time employees. The company went IPO on 2003-05-28. The firm is in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease; progressive multiple sclerosis (PMS); Alzheimer’s disease (AD); and other neurodegenerative diseases. Its NurOwn, a cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived MSCs to secrete high levels of neurotrophic factors (NTFs), modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. The company has completed a Phase III pivotal trial in ALS (NCT03280056); this trial investigated the safety and efficacy of repeat-administration of autologous MSC-NTF cells. The firm's wholly owned subsidiary, Brainstorm Cell Therapeutics Ltd. holds exclusive rights to commercialize NurOwn technology.
Can you provide the latest stock price for BRAINSTORM CELL THERAPEUTICS?
The current stock price of BCLI is 1.17 USD. The price decreased by -2.5% in the last trading session.
Does BCLI stock pay dividends?
BCLI does not pay a dividend.
What is the ChartMill technical and fundamental rating of BCLI stock?
BCLI has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Where is BRAINSTORM CELL THERAPEUTICS (BCLI) stock traded?
BCLI stock is listed on the Nasdaq exchange.
Is BRAINSTORM CELL THERAPEUTICS (BCLI) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on BCLI.